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 SUMMARY 
 
Numerous neurodegenerative disorders result from the aggregation of proteins that misfold 
and accumulate as fibrillar amyloid deposits in selectively vulnerable regions of the central 
nervous system. Alzheimer’s disease (AD) is one of these protein conformational diseases 
and the leading cause of dementia in the Western world. Postmortem, it is characterized by 
two major neuropathological features: extracellular deposition of Abeta (Aβ) peptide and 
intracellular aggregates of neurofibrillary lesions made of hyperphosphorylated tau protein. 
The observation that early-onset familial forms of AD are caused by mutations in three 
genes (the amyloid precursor protein (APP), presenilin-1 (PS1), and presenilin-2 (PS2)), all 
of which increase the production of Aβ, led to the so-called amyloid cascade hypothesis. 
This hypothesis proposed that the aggregation of polymerized forms of Aβ in soluble 
multimeric and/or insoluble senile plaque deposits in the brain is an early and critical event 
that triggers a cascade of pathological events leading to hyperphosphorylation and 
somatodendritic segregation of tau, formation of neurofibrillary lesions, 
neuroinflammation, neurodegeneration and, finally, dementia. 
 
The generation of transgenic (tg) mice that exhibit cerebral Aβ-amyloidosis through 
expression of mutated human APP gene has provided new opportunities to explore 
pathogenic mechanisms and treatments of AD. The studies presented below were done in 
part using the well-established APP23 tg mouse model that carries human KM670/671NL 
mutated APP under the control of a neuron specific Thy-1 promoter and develops amyloid 
deposits progressively with age. We also generated and made use of a novel tg model, the 
APPPS1 mouse. This model coexpresses KM670/671NL mutated APP and L166P mutated 
PS1 that lead to accelerated cerebral amyloidosis concomitantly with additional AD-like 
pathologies such as local neuron loss, hyperphosphorylated tau-positive neuritic structures, 
dystrophic synaptic boutons and robust cortical gliosis. Because of the early onset of 
amyloid pathology, APPPS1 mice are well suited for studying the mechanism and impact 
of cerebral amyloidosis and to test therapeutic amyloid-targeting strategies. 
 
The aggregation of Aβ protein is an established pathogenic mechanism in Alzheimer’s 
disease, however little is known about the initiation of this process in vivo. The first set of 
experiments were therefore performed to characterize the induction of cerebral Aβ-
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 amyloidosis in vivo, and to clarify which factors are involved in the seeding process. We 
show that aggregation of Aβ can be exogenously induced in a time- and concentration-
dependent manner by injecting Aβ-containing brain extracts from humans with Alzheimer's 
disease or APP23 tg mice into the brains of young APP23 tg host mice. By injecting 
extracts from APPPS1 tg mice into APP23 hosts and vice versa, our results suggest that 
characteristics of both the brain extract and the host are important in governing the 
phenotype of the induced amyloid. Intriguingly, intracerebral injections of synthetic 
fibrillar Aβ preparations as well as cell culture-derived Aβ  in concentrations similar to 
brain extract levels were not able to seed Aβ aggregation in vivo. And yet the seeding 
requires an aggregated form of Aβ, because formic acid denaturation and Aβ-
immunodepletion abolished the Aβ-inducing activity of the extract. Last but not least, we 
show that β-amyloid-induction is halted by Aβ-immunization of the host, demonstrating 
that the earliest stages of cerebral Aβ-amyloidosis deposition are amenable to therapeutic 
intervention. 
 
AD presents morphologically with abundant neurofibrillary lesions, but the events that 
initiate tau pathogenesis in vivo remain unclear. Thus, the second series of experiments 
were performed to characterize the induction of tau pathology in vivo, as well as to identify 
potential tau-inducing candidates. We show that intracerebral injection of Aβ-containing 
brain extract from human with AD or β-amyloid-laden APP23 mouse induces 
neurofibrillary pathology in transgenic mice expressing human tau with the P301L 
mutation. Importance of soluble Aβ species for exogenous induction of tau pathogenesis 
was demonstrated by intracerebral injection of human brain extract with low Aβ level. 
Notably, intracerebral injection of brain extract from aged tangle-bearing P301L transgenic 
mouse induced only limited deposition of tau in brains. Our results show that 
neurofibrillary pathology is exogenously induced by extracts from Aβ-containing brains, 
and provide further support for the hypothesis that Aβ is a causative pathogenic factor of 
AD. 
 
It has long been recognized that microglial cells react to β-amyloid deposition as to other 
brain injuries, but various aspects of their reactive kinetics and ability to phagocytose 
amyloid in vivo remain hypothetical, despite their potential as therapeutic target. To resolve 
these controversies, we have designed in a third series of experiments a set of robust 
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 analysis tools centered around intracranial multiphoton imaging to characterize the time-
course and extend of microglia’s response to amyloid deposition in tg mice. By following 
individual plaques and microglia over time in the living brain, we have shown that plaque 
formation was accompanied by microglial process extension and subsequent migration to 
the site of injury where individual microglia then exhibited signs of uptake of the Aß 
peptide. Furthermore, by infusing fluorescent Aß-antibody into the brain parenchyma we 
demonstrated that the interaction of microglia with plaques can be stimulated, leading to 
further internalization of Aß and at least partial clearance of existing dense deposits. 
Together, these results demonstrate an ongoing dynamic homeostasis between plaques and 
microglia that is amenable to therapeutic intervention. 
 
In summary, the experiments described herein have increased our understanding of the 
mechanisms underlying the initiation of cerebral Aβ-amyloidosis and neurofibrillary 
pathology in vivo. We have shown that cerebral Aβ-amyloidosis can be induced by 
exogenous, Aβ-rich brain extract, and that intrinsic properties of the Aβ in the extract as 
well as of the host are crucial for the induction of Aβ accumulation in brain. We also 
demonstrated that neurofibrillary pathology can be induced in vivo by intracerebral infusion 
of Aβ-rich brain extract into a susceptible transgenic host, and that soluble Aβ species are 
potent effectors of tau pathology in the brain. Moreover, our observations that interaction of 
microglial cells with amyloid plaques can be stimulated, such that these cells are induced to 
clear existing Aβ deposits, provide the mechanistic clues necessary for development of 
additional therapeutic targets for amyloid clearance. 
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 1.1.Protein misfolding and amyloid formation in degenerative disorders 
 
Proteins are involved in virtually every biological process in a living system. They are 
synthesized on ribosomes as linear chains of amino acids in a specific order from 
information encoded within the cellular DNA. In order to perform their biological function 
these chains of amino acids must fold into the native three-dimensional structures that are 
characteristic of the individual proteins. How and whether a protein folds is influenced 
primarily by its amino acid sequence and the cellular environment surrounding the amino 
acid chain (Anfinsen, 1973; Jackson, 1998; Baldwin and Rose, 1999; Horwich, 1999). 
Mutations, abnormal physiological concentrations, coupled with prolonged time and certain 
biochemical conditions are thought to destabilize the native three-dimensional state, or 
divert soluble proteins from their normal folding pathway, often leading to their 
aggregation into stable insoluble amyloid deposits. Numerous degenerative diseases arise 
due to the build up of insoluble misfolded protein deposits (Kelly, 1996; Dobson, 1999; 
Rochet and Lansbury, 2000; Hetz and Soto, 2003). These proteopathies include 
neurological disorders such as bovine spongiform encephalopathy and its human equivalent 
Creutzfeld-Jakob disease, and also Alzheimer's disease, Parkinson's disease, Huntington’s 
disease, in addition to diverse systemic amyloidosis (Carrell and Lomas, 1997; Prusiner, 
1998; Rochet and Lansbury, 2000; Walker and Levine, 2000; Selkoe, 2003) (Table 1). 
 
No sequence or structural similarities are apparent between any of the proteins that display 
the ability to form amyloids. Despite these differences, the fibrils formed by different 
polypeptides share a number of structural characteristics (Serpell et al., 1997; Sunde et al., 
1997; Dobson, 2003). For example, X-ray fiber diffraction studies indicate that the peptide 
backbone of the fibers adopts a cross β-structure (Sunde and Blake, 1997; Blake and 
Serpell, 1996; Guijarro et al., 1998; Chiti et al, 1999). In this structure, the individual β-
strands are oriented perpendicular to the long axis of the fiber, while the hydrogen bonds 
are oriented parallel with the long axis of the fiber (Blake et al, 1996; Wetzel, 2002). 
Amyloid fibers are also resistant to proteolysis, and display characteristic apple-green 
birefringence when stained with the histological dye Congo red and seen under polarized 
light (Sunde et al., 1997). There are also striking similarities in the aggregation behavior of 
many misfolded proteins, even if their propensity to aggregate can vary markedly between 
different sequences (Chiti et al., 2003). Amyloid fibrils are thought to form through self-
assembly of protein monomers via a nucleation dependent pathway initiated in partially 
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 denatured states of amyloidogenic proteins (Jarret et al., 1993; Jarrett and Lansbury, 1993; 
Harper and Lansbury, 1997; Kelly, 1998; Kayed et al., 1999; Scherzinger et al., 1999; 
Wood et al., 1999; Maioli et al., 2000; Yao et al., 2003; Dobson, 2004). However, even 
though the formation of fibrils via a nucleation-dependent pathway seems to be generic, 
most of the studies to date have been done in vitro and may not mimic the situation in 
human diseases (Wetzel, 2002; Buxbaum, 2003). The nucleation-dependent polymerisation 
mechanism is similar to the highly ordered process of protein crystallization (Harper et al., 
1997). This mechanism dictates that aggregation is dependent on protein concentration and 
time, and consists of an initial nucleation (or lag) phase followed by an elongation (or 
growth) phase and a steady state phase in which the protein aggregates and monomer are at 
equilibrium (Harper and Lansbury, 1997). In a typical nucleation-dependent 
polymerization, oligomerization is not observed until the monomer concentration exceeds a 
certain level known as the critical concentration. During the lag phase protein associates in 
a supersaturated solution to form ordered soluble oligomeric nuclei, but no detectable fibers 
 Disease Protein Involved 
Alzheimer's disease Amyloid β-peptide 
Spongiform encephalopathies Prion protein 
Hereditary cerebral hemorrhage 
with amyloidosis 
Amyloid β-peptide or cystatin C 
Type II diabetes Amylin (Islet amyloid polypeptide) 
Medullary carcinoma of the thyroid Procalcitonin 
 
Organ-
limited extra 
cellular 
amyloidoses 
Atrial amyloidosis Atrial natriuretic factor 
Primary systemic amyloidosis Intact Ig light chains or fragments 
Secondary systemic amyloidosis Fragments of serum amyloid A protein 
Familial Mediterranean fever Fragments of serum amyloid A protein 
Familial amyloidotic 
polyneuropathy1 
Mutant transthyretin and fragments 
Senile systemic amyloidosis Wild-type transthyretin and fragments 
Familial amyloidotic 
polyneuropathy II 
Fragments of apolipoprotein A-1 
Haemodialysis-related amyloidosis 2-Microglobulin 
Finnish hereditary amyloidosis Fragments of mutant gelsolin 
Lysozyme amyloidosis Full-length mutant lysozyme 
Insulin-related amyloid Full-length insulin 
 
 
 
Systemic 
extra 
cellular 
amyloidoses 
Fibrinogen α-chain amyloidosis Fibrinogen α-chain variants 
Alzheimer's disease Amyloid β-peptide, Tau 
Frontotemporal dementia with 
parkinsonism 
Tau 
Parkinson's disease; dementia with 
Lewy bodies 
α-Synuclein 
Creutzfeldt-Jakob disease Prion protein 
Polyglutamine expansion diseases Long glutamine stretches within certain 
proteins 
 
 
 
Intracellular 
amyloidoses 
Amyotrophic lateral sclerosis Superoxide dismutase 
 
Table 1. List of diseases resulting from amyloid formation (adapted from Selkoe, 2003) 
 
 9
 are formed. Addition of preformed protein nuclei during the lag time results in immediate 
polymerization, a process known as seeding (Harper et al., 1997). Once the oligomeric 
nuclei are formed, the aggregates grow rapidly (elongation phase) until a thermodynamic 
equilibrium between the aggregate and monomer is reached (Harper et al., 1997; Walsh et 
al., 1997). 
 
Alzheimer’s disease is a member of the amyloid disease group, wherein two major kinds of 
protein aggregates are key contributors to the pathogenesis (Hardy et al., 1998; Hardy and 
Selkoe, 2002). Extracellular aggregates known as neuritic plaques have their major 
constituent the Aβ peptide, which is derived from proteolytic processing of the amyloid 
precursor protein (APP). The Aβ-containing aggregates have β-sheet structure and Congo 
red and thioflavin-T reactivity characteristic of amyloid (Serpell and Smith, 2000). The 
aggregation process that converts soluble Aβ into amyloid fibrils in vitro is thought to be a 
nucleation-dependent process (Harper and Landsbury, 1997). In AD, there are also 
intracellular aggregates of the microtubule-associated protein tau, called neurofibrillary 
lesions. The molecular structure of tau filaments has been controversial but there is 
consensus now that tau fibrils in AD fit the amyloidosis definition (Berriman et al., 2003). 
Kinetics datas support the view that tau fiber may also form via a nucleation-dependent 
mechanism, tau oligomerization and nucleation events being the rate-limiting step in 
filament formation (Friedhoff et al., 1998; King et al., 1999). Nevertheless, the major 
caveat remains that we have yet to learn how these aggregational events begin in vivo and 
how their development lead to the progressive behavioral and cognitive demise that 
characterizes the human disease. 
 
 
 
 
1.2.Alzheimer’s disease 
 
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive 
cognitive deterioration together with declining activities of daily living and 
neuropsychiatric symptoms or behavioral changes. The symptoms of the disease as a 
distinct entity were fist identified by Emil Kraepelin, and the characteristic neuropathology 
first observed by Alois Alzheimer, a German psychiatrist, in 1906. 
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 1.2.1. Clinical symptoms and diagnosis 
 
Alzheimer’s original patient (Alzheimer, 1907) exemplified several cardinal features of the 
disorder that we still observe in most patients nowadays. One of the first noticeable 
symptoms is short-term memory loss, which usually manifests as minor forgetfulness that 
becomes more pronounced with illness progression, with relative preservation of older 
memories (Morris et al., 1989; Petersen et al., 1999). It is difficult to distinguish these 
earliest disease-related cognitive changes of AD from those associated with normal aging 
(Small, 2001; Collie et al., 2001; Morris et al., 2001). As the disorder progresses, cognitive 
impairment extends to the domains of language, skilled movements, recognition, and 
executive functions (Morris et al., 1989; Morris, 1996). As subjects continue to lose ground 
cognitively, slowing of motor functions such as gait and coordination often lead to a picture 
resembling extrapyramidal motor disorders (Selkoe, 2001). In the final stages, patients 
become immobile and die of respiratory difficulties such as pneumonia (Fotstl and Kurz, 
1999). Average duration of the disease is approximately 7-10 years, although cases are 
known where reaching the final stage occurs within 4-5 years, or up to 15-20 years (Fotstl 
and Kurz, 1999). 
 
Although definitive diagnosis requires a postmortem neuropathological examination, 
neurologists and neuropsychologists have now developed clinical criteria that often lead to 
~90% accuracy in diagnosing AD. To make the diagnosis of AD and to exclude other 
causes of dementia, clinicians rely on histories from patients and informants; physical, 
neurological, and psychiatric examinations; neuropsychological testing; laboratory 
assessments; and a variety of other diagnostic tests including neuroimaging (Clark and 
Karlawish, 2003). Biochemical changes that reflect the presence of disease-related 
pathology also have the potential to serve as diagnostic biomarkers of Alzheimer disease 
(Growdon, 1999). To date, the most extensively studied biochemical markers are the 
cerebrospinal fluid proteins tau and β-amyloid (Andreasen et al., 2001; Knopman, 2001). 
Both are particularly relevant to the pathology of Alzheimer disease and thus may provide 
diagnostically useful information.  
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 1.2.2. Neuropathological phenotype 
 
The classical pathophysiology of AD includes extensive neuronal degeneration and synapse 
loss resulting in marked atrophy of brain regions critical for learning and memory (Fig.  1, 
A), together with an inflammatory response to the deposition of senile plaques and 
neurofibrillary lesions (Fig.  1, B and C, respectively) (Terry et al., 1991; West et al., 1994; 
Gomez-Isla et al., 1996, Selkoe, 2001). The interaction between amyloid plaques, 
neurofibrillary tangles, their constituent molecules and the neuronal and synaptic losses that 
characterize the disease has been the subject of speculations for many years and still 
remains an unresolved issue. 
 
 
  1.2.2.1. β-amyloid plaques and the Aβ centric theory of Alzheimer’s 
 
Neuritic or senile plaques are one of the histopathological hallmarks of AD. Senile plaques 
are extracellular deposits primarily composed of β-amyloid (Aβ) protein that are 
surrounded by dystrophic axons as well as the processes of astrocytes and microglia (Arai 
et al., 1990, 1992; Schmidt et al., 1991; Masliah et al., 1992; Trojanowski et al., 1993; 
Dickson, 1997; Selkoe, 1999, 2001; Masters et al., 2006). In addition and at least to some 
 
 
Figure 1. The neuropathological hallmarks of AD. Characteristic pathophysiological changes include loss of
neurons, neuronal processes and synapses in the cerebral cortex and certain subcortical regions. These
changes are associated with gross atrophy of the affected regions and enlargement of the lateral ventricules
(A). Histological stainings of senile plaques (B) and neurofibrillary tangles (C) in an AD brain. 
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 degree, Aβ deposits are also apparent within the walls of leptomeningeal and cerebral 
vessels (Selkoe et al., 1987; Vinters, 1987; Yamada et al., 1987; Martin et al., 1991; 
Jellinger, 2002). The evolution of Aβ deposits in the brain follows a distinct sequence in 
which the regions are hierarchically involved (Thal et al., 2002). The first phase is the 
neocortical phase 1, followed by the allocortical phase 2. In phase 3, the diencephalic 
nuclei, the striatum and the cholinergic nuclei of the basal forebrain develop Aβ deposits, 
and in phase 4 several brainstem nuclei become additionally involved. Finally, phase 5 is 
characterized by cerebellar Aβ deposition.  
 
The principal constituent of plaques is Aβ (Glenner and Wong, 1984; Masters et al., 1985; 
Selkoe et al., 1986), a 4 kDA protein fragment of 39-43 amino acids which is formed after 
sequential cleavage of the amyloid precursor protein (APP) by the β- and γ-secretases (see 
section 1.2.3.) (Cappai and White, 1999; Selkoe, 2001). Much of the fibrillar Aβ found in 
the neuritic plaques is the species ending at amino acid 42 (Aβ42), the slightly longer, less 
soluble form that is particularly prone to aggregation (Jarrett et al., 1993b; Harper et al., 
1997c). However, the Aβ species ending at amino acid 40 (Aβ40), which is normally more 
abundantly produced by cells than Aβ42, is usually colocalized with Aβ42 in the plaque 
(Iwatsubo et al., 1994). Within amyloid deposits and immediately surrounding them, 
neurites are marked by ultrastructual abnormalities that include enlarged lysosomes, 
numerous mitochondria, and paired helical filaments (PHFs) (Arai et al., 1990; Schmidt et 
al., 1991; Masliah et al., 1992; Trojanowski et al., 1993; Dickson, 1997; Selkoe, 2001). 
Senile plaques are also surrounded by reactive astrocytes displaying abundant glial 
filaments, and are also intimely associated with microglia expressing surface antigens 
associated with activation, such as CD45 and HLA-DR (Itagaki et al., 1989; McGeer and 
McGeer, 1995; Rogers et al., 1996). Microglia represent the macrophage-derived cells in 
the nervous system that are capable of responding rapidly to various types of insults 
(Nimmerjahn et al., 2005; Davalos et al., 2005). Thus, these cells represent reasonable 
candidates for early cellular respondents of β-amyloid deposition. Nevertheless, microglia 
and astrocytes are also involved in the overproduction and release of various inflammatory 
mediators, leading to profound inflammatory disturbance in limbic and association cortices 
observed in AD (Abraham et al. 1988; Griffin et al., 1989; Rogers et al., 1992; Itagaki et 
al., 1994). 
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 Many of the plaques found in limbic and association cortices but also thalamus, caudate, 
putamen, and cerebellum, show relatively light, amorphous Aβ immunoreactivity that 
occurs without a compacted fibrillar center (Yamaguchi et al., 1988; Joachim et al., 1989). 
These lesions that are referred to as “diffuse” plaques, contain mainly Aβ42 species with 
little or no Aβ40 (Gowing et al., 1994; Iwatsubo et al., 1994, 1995; Lemere et al., 1996) 
and lack neuritic dystrophy, glial changes and PHFs (Selkoe, 1991; Dickson, 1997; Selkoe, 
2001). In contrast to the Aβ deposited in compact senile plaques, diffuse deposits are not 
detected with Congo red or other dyes, such as Thioflavin S, that bind amyloid. Moreover, 
they are also observed in normal ageing individuals, but the density is lower than in AD 
patients (Perry et al., 1978). It has been suggested that diffuse plaques may represent 
precursors to the classical neuritic plaques (Tagliavini et al., 1988; Yamaguchi et al., 1988; 
Iwatsubo et al., 1996; Lemere et al., 1996; Masters et al., 2006). This hypothesis is best 
illustrated by studies of Down's syndrome. Here, patients have little or no Aβ deposition in 
the first decade of life, but by around 12 years, one begins to see diffuse plaques containing 
Aβ42 (not Aβ40), and more and more Down's subjects develop such plaques during the 
second and third decade of life (Lemere et al, 1996). Then, after the age of 30 years, one 
begins to see amyloid fibril formation in plaques and there is associated microgliosis, 
astrocytosis and some neuritic dystrophy. These neuritic plaques become then more 
prevalent over the next 2 decades of life. A model for the deposition of Aβ in amyloid 
plaques consistent with the view that diffuse plaques represent immature precursors to the 
plaques with surrounding cytopathology is illustrated in the Figure 2. 
 
It has been more than 15 years since it was first proposed that the neurodegeneration in 
Alzheimer's disease (AD) may be caused by deposition of Aβ peptide in plaques (the 
amyloid cascade hypothesis) (Hardy and Allsop, 1991). According to this hypothesis, 
accumulation of Aβ fibrils in the brain is the primary influence driving AD pathogenesis. 
The rest of the disease process, including formation of neurofibrillary lesions containing tau 
protein, microgliosis, synaptic dysfunction and neuronal loss is proposed to result from an 
imbalance between Aβ production and Aβ clearance. The pathogenic role of β-amyloid 
deposition in AD is underscored by the evidence that each of the disease-causing mutations 
in familial AD results in enhanced production of amyloidogenic Aβ peptides (Hardy and 
Selkoe, 2002). Although the large Aβ aggregates present in plaques were initially regarded 
as the culprits responsible for neurodegeneration, the distribution and density of both 
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 diffuse and senile plaques at the light microscopic level have not been consistently shown 
to correlate well with the degree of cognitive impairment that the patient experienced in life 
(Terry, 1991; Berg et al., 1998; Hardy et al., 1998; McLean et al., 1999; Wang et al., 1999). 
Moreover, abundant cortical Aβ deposits may also be found in cognitively intact ederly 
subjects (Dickson et al., 1991; Arriagada et al., 1992). The best correlation with the degree 
of dementia occurs with soluble levels of Aβ, measured biochemically (Lue et al., 1999; 
Mc Lean et al., 1999; Wang et al., 1999; Naslund et al., 2000). In accordance with these 
observations, several lines of evidence have recently converged to demonstrate that soluble 
oligomeric assemblies of Aβ, but not insoluble amyloid fibrils, may be responsible for the 
loss of neurons and synaptic dysfunction observed in AD (Klein et al., 2001; Kirkitadze et 
al., 2002; Selkoe, 2002). Importantly, such oligomeric forms of Aβ have been shown to be 
neurotoxic both in vitro and in vivo (Oda et al., 1995; Walsh et al., 1997; Lambert et al., 
1998; Hartley et al., 1999; Walsh et al., 1999; Nilsberth et al., 2001, Walsh et al., 2002) and 
to inhibit long-term potentiation (Walsh et al., 2002). These evidence supports a revision of 
the amyloid cascade hypothesis such that Aβ assembly into neurotoxic oligomers, and not 
into amyloid fibrils, is the seminal event in AD pathogenesis (Klein et al., 2001, 2004; 
Figure 2. Hypothetical mechanism for the deposition of Aβ in amyloid plaques. Soluble Aβ peptides
(depicted by the ref filled circles) are produced in neurons (N=nucleus of a cell) and secreted (A) into the
extracellular space (B) from whence they are cleared in the brains of normal young individuals (C). With
advancing age, soluble Aβ aggregates into diffuse plaques (closely packed filled circles to the right of the D).
Some aggregated soluble Αβ also may be cleared from these plaques (E). In AD, soluble Aβ in diffuse
plaques may be induced to form fibrillar Aβ aggregates that lead to the formation of mature senile plaques
(to the right of the F) which accumulate many additional components including more soluble Aβ, PHFs
(curvilinear black profiles), in addition to microglial cells (I) and reactive astrocytes (H). Nonfibrillar or
soluble Aβ might be cleared from senile plaques (G), but the continued presence of factors that induce the
fibrillogenesis and insolubility of soluble Aβ would favour the persistence of amyloid in the AD brain. 
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 Kirkitadze et al., 2002; Walsh et al., 2002b). It might well be that fibrillar amyloid acts as a 
reservoir for the soluble oligomers, or represent the sequestered pool of soluble and now 
precipitated Aβ, therefore fulfilling a protective function, or just the end stage of the Aβ 
cascade (Masters et al., 2006). 
 
 
  1.2.2.2. Neurofibrillary lesions 
 
The second histopathological hallmark of AD is the neurofibrillary lesions (NFLs). NFLs 
are intracellular filamentous deposits largely composed of microtubule-associated protein 
tau in a hyperphosphorylated and abnormally phosphorylated state (Brion et al., 1985; 
Grundke-Iqbal et al., 1986; Nukina and Ihara, 1986; Wood et al., 1986; Kosik et al., 1988; 
Goedert, 1993; Lee, 1995; Morishima-Kawashima et al., 1995). There are three main types 
of NFLs according to their localizations in nerve cells: (i) neurofibrillary tangles (NFTs) in 
the cell body and apical dendrites of neurons, (ii) neuropil threads (NTs) in distal dendrites 
and (iii) dystrophic neurites associated with neuritic plaques (Tolnay and Probst, 1999). 
Ultrastructurally, NFLs contain bundles of abnormal fibers that consist of pairs of ~10nm 
filaments wound into helices (paired helical filaments or PHFs) as a major fibrous 
component and straight, 10- to 15-nm filaments (or SFs) as a minor component (Selkoe, 
2001). Most of these filaments are highly insoluble and resistant to detergent such as 
sodium dodecyl sulfate (Selkoe et al., 1982). Tau proteins are the major, if not the sole, 
building block of PHFs in the major NFLs of the AD brain. However, 
immunohistochemical studies have demonstrated that PHFs also contain neurofilament 
proteins (Anderton et al., 1982; Perry et al., 1985; Sternberger et al., 1985; Miller et al., 
1986), actin (Vogelsang et al., 1988), ubiquitin (Mori et al., 1987; Perry et al., 1987), 
MAP2 (Yen et al., 1987) and Aβ protein (Kidd et al., 1985; Masters et al., 1985). Although 
very poorly documented, the appearance and development of NFLs is associated with an 
inflammatory response, indicated by a progressive microglial and astrocytic reaction to tau 
deposition (Perlmutter et al., 1992; Sheng et al., 1997). 
 
The manner in which neurofibrillary pathology spreads to various brain areas during the 
course of AD is not random but follows a stereotyped pattern which has been used to define 
six neuropathological stages, the Braak stages (Braak and Braak, 1991). On the basis of 
cross-sectional analysis of unselected cases coming to post-mortem, Braak and Braak have 
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 reported that neurofibrillary tangles are first observed in the transentorhinal and entorhinal 
cortex (stages I and II or transentorhinal stages). A more extensive involvement of the 
entorhinal cortex and the formation of NFTs in sector CA1 (Cornu Ammonis 1) of the 
hippocampus correspond to stages III and IV or to limbic stages. Pathology then spreads 
into sectors CA2, 3 and 4 of the hippocampus, the subiculum, and into isocortical areas, 
particularly the temporal and parietal cortices (Stage V). The final stage VI is characterized 
by more extensive spread in neocortical areas, with relative sparing of primary motor and 
sensory areas. There is a close correlation between the burden of NFTs and the degree of 
dementia in AD, at least in some cortical and subcortical regions (Bondareff et al., 1989; 
Arriagada et al., 1992; Holzer et al., 1994; Bierer et al., 1995). At Braak stages I and II, 
patients are cognitively unimpaired whereas subjects with limbic stages III and IV usually 
present with mild cognitive impairment. Subjects with stages V and VI are severely 
demented and meet the neuropathological tau criteria for the diagnosis of AD.  
 
Morphologically, three main subtypes of NFTs can be distinguished, corresponding to 
different evolutionary stages of this lesion (Tolnay and Probst, 1999). The earliest stage, 
also termed pretangle stage, is characterized by the accumulation of hyperphosphorylated 
tau protein in the somatodendritic domain of affected neurons without formation of PHFs 
and SFs (Bancher et al., 1989; Braak et al., 1994). Therefore pretangle neurons are only 
detectable with anti-tau antibodies in contrast to the later stage of classical NFT formation 
wherein tau aggregates are identified with silver staining techniques such as Bielschowsky 
and Gallyas stains. The third stage of NFT formation corresponds to extracellular NFTs or 
“ghost” tangles (Tolnay and Probst, 1999; Bancher et al., 1989). It has been proposed that 
the release of NFTs from dying neurons could result in interactions between aggregated tau 
and the soluble Aβ normally secreted by neurons or other brain cells (Seubert et al., 1992; 
Shoji et al., 1992; Wertkin et al., 1993Trojanowski et al., 1993; Trojanowski and Lee, 
1994). Thus, the chronic but progressive degeneration of neurons in the AD brain may 
release NFTs into the extracellular space, which then are able to recruit or immobilize 
soluble Aβ into deposits. These same neuronal debris also may play a role in inducing 
aggregated Aβ to undergo fibrillogenesis and the formation of neuritic amyloid plaques 
(Shin et al., 1993, 1994). These data intersect well with the work of Braak and Braak 
(1991) who stated that initial NFTs predate morphologically detectable amyloid plaques. 
However, as Hardy and Selkoe (2002) point out, the postmortem cases used to establish the 
Braak stage I neuropathology criteria were non-demented older individuals, in whom it is 
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 impossible to conclude that they would all have developed AD if they had survived longer. 
Second, the Braak analysis cannot exclude a toxic effect of any soluble oligomeric forms of 
Aβ that have not yet reached the stage of microscopically visible amyloid plaques. 
Moreover, in patients with the rare presenilin 1 mutations or individuals with Down’s 
syndrome who died prematurely from other diseases, the presence of Aβ (either as diffuse 
deposits or typical plaques) precedes the appearance of neurofibrillary tangles (Lemere et 
al., 1996; Lippa et al., 1998).  
 
PHFs resembling those of AD have been assembled from recombinant tau in vitro. This 
process is usually very slow (days or weeks), corresponding to the highly soluble nature of 
tau. Several principles have emerged from these in vitro studies over the past few years; the 
repeat domain of tau is important for PHF aggregation (Wille et al., 1992; Wilson and 
Binder, 1995; DeTure et al., 1996); aggregation is strongly enhanced by oxidation (Wille et 
al., 1992; Schweers et al., 1995) or in the presence of polyanions such as heparin, 
ribonucleic acids, or acidic peptides (Perez et al., 1996; Goedert el al., 1996; Kampers et 
al., 1996); mutations of tau found in hereditary frontotemporal dementia and parkinsonism 
linked to chromosome 17 (FTDP-17) favor tau aggregation and PHF formation (Barghorn 
et al., 2000; Goedert et al., 1999; Gamblin et al., 2000; Hong et al., 1998). The reasons for 
this may be heterogeneous, depending on the type of mutation but at least in the cases of 
P301L they can be traced back to an enhanced propensity for β-structure, a feature common 
to many pathological amyloids (Fraser et al., 1994; Pike et al., 1995; Lansbury, 1997). In 
AD, PHF formation is not due to mutations in the tau gene but rather to some cellular 
cascade triggered by Aβ that results in abnormal phosphorylation of tau proteins that causes 
them to assemble into filaments. This statement intersects well with the observation that Aβ 
in the vicinity of neurons enhanced tau phosphorylation in vitro and in vivo (Busciglio et 
al., 1995; Geula et al., 1998). This is further supported in a recent article showing that 
double transgenic mice expressing mutant human tau (P301L) and mutant APP developed 
enhanced neurofibrillary pathology and degeneration in cortical and subcortical brain 
regions (Lewis et al., 2001). Moreover, recent work has indicated that direct intracranial 
injection of synthetic Aβ peptide increases tau phosphorylation and NFT formation in 
transgenic mice expressing the P301L tau mutant (Gotz et al., 2001). Although the 
molecular mechanism by which the extracellular accumulation of Aβ peptides promotes the 
intracellular assembly of pathologic tau filaments in vivo remains poorly unterstood, a 
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 mechanistic link between the two is emerging. Exposure of primary neurons to Aβ activates 
the tau kinase GSK3β (glycogen synthase kinase β), increases tau phosphorylation, and 
leads to cell death (Takashima et al., 1998; Zheng et al., 2002). The tau kinase cdk5 (cyclin-
dependent kinase 5) is also activated by Aβ in cultured neurons and in AD (Dhavan and 
Tsai, 2001). The activity of the cdk5 kinase is regulated by a 35-kDa myristoylated 
membrane-attached protein, p35 (Zheng et al., 2002b). When p35 undergoes calpain-
mediated cleavage to p25, kinase activity is greatly enhanced. The cdk5/p25 complex 
appears to be delocalized from the plasma membrane, leading to nonphysiologic 
phosphorylation of tau, its dissociation from microtubules and self-assembly into insoluble 
filaments (Michealis, 2002). 
 
 
1.2.3. Epidemiology and genetics of Alzheimer’s disease 
 
AD is the most common cause of dementia (Table 2) and affects approximately 7% of 
people older than 65 and perhaps 40% of people over the age of 80 (McKhann et al., 1984; 
Evans et al., 1989; Rocca et al., 1991; Ebly et al., 1994; Lautenschlager et al., 1996; Lobo 
et al., 2000). Because of increased life expectancy and the post-World War II baby boom, 
the elderly is the fastest growing segment of our society (Olshansky, 1993). More than 
twelve million people worldwide now suffer from AD, a striking figure that is predicted to 
almost triple by 2050 (Hebert et al., 2003). Thus, AD is one of society’s major public health 
problems. 
 
The vast majority of AD cases are sporadic and occur late in life with no clearly defined 
etiology. However, genetic factors are known to be important and, in fact, after age, family 
history is the second greatest risk factor for AD (Selkoe, 1999). Autosomal dominant 
mutations in three different genes (amyloid precursor protein, presenilin 1 and presenilin 2) 
have been identified that account for a small number of cases of familial, early-onset AD 
(FAD) (Schellenberg, 1995; Kim and Tanzi, 1997). The first genetic mutation associated 
with FAD was in the APP gene. Suspicion of the involvement of APP in FAD arose since 
the gene resides on chromosome 21 (Kang et al., 1987) and people with Down’s syndrome 
(who have an extra copy of chromosome 21) develop neuropathological attributes of AD by 
age 40 (Wisniewski et al., 1985). Genetic linkage studies also suggested the involvement of 
a locus near the APP gene on chromosome 21 in FAD (Tanzi et al., 1987; Goate et al., 
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 1989). In 1991 the first genetic linkages of AD were identified as missense mutations in the 
APP gene located on chromosome 21 (Naruse et al., 1991; Goate et al., 1991). Since then, 
more than 20 pathological mutations in APP have been identified (Figure 6). Most of these 
are near the proteolytic cleavage sites involved in Aβ production (Goate et al., 1991; 
Hendriks et al., 1992; Mullan et al., 1992; Ghiso and Frangione, 2002). Mutations in APP 
do not account for all cases of FAD. In the mid 1990s, further genetic linkage studies 
uncovered mutations in presenilin 1 on chromosome 14 (St George-Hyslop et al., 1992; 
Sherrington et al., 1995) and presenilin 2 on chromosome 1 (Levy-Lahad et al., 1995; 
Rogaev et al., 1995). Presenilin forms the active site of the γ-secretase complex involved in 
the production of Aβ (De Strooper, 2003). To date there are more than 120 different 
mutations identified in the PS1 gene, while only 8 missense mutations have been identified 
in PS2. FAD mutations in PS1, PS2 and APP result in overproduction of total Aβ and/or 
lead to an increase of secreted Aβ42, the primary component of β-amyloid plaques in the 
brain (Tamaoka et al., 1994; Hardy, 1997; Price an Sisodia, 1998; Selkoe, 1999; Haass and 
DeStrooper, 1999). 
 
Figure 3. Structure of the β-amyloid precursor protein (APP, in blue), the β-amyloid (Aβ, in red), and
missense mutations located within APP. APP is proteolytically cleaved by sequential actions of α-, β-, and γ-
secretases (indicated by the scissors). The location of APP mutations associated with early-onset familial AD
(FAD) and/or cerebrovascular pathology are marked by asterisks and the amino acid substitutions are
indicated. 
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 In addition to the mutations that have been associated with early-onset FAD, other genetic 
factors have been identified that increase the risk of developing sporadic AD. These include 
the ε4 allele of the apolipoprotein E (ApoE) gene (Strittmatter et al., 1993) on chromosome 
19 (Olaisen et al., 1982), the proteinase inhibitor α2-macroglobulin gene (Blacker et al., 
1998) on chromosome 12 (Pericak-Vance et al., 1997), insulin degrading enzyme gene on 
chromosome 10 (Vekrellis et al., 2000), low density lipoprotein receptor-related protein 
(Olson, 1998) or angiotensin converting enzyme (Kehoe et al., 1999). 
 
At present, no mutations in the tau gene have been identified in AD. Nevertheless, several 
mutations in human tau on chromosome 17 result in a cluster of neurodegenerative 
diseases, termed FTDP-17, that are characterized by the accumulation of neurofibrillary 
tangles in affected brain regions (Hutton et al., 1998; Poorkaj et al., 1998; Spillantini et al., 
1998). They include missense mutations in coding regions of the tau gene in exons 9, 10, 
12 and 13, silent mutations as well as a deletion mutation in exon 10, and intronic 
mutations located close to the splice-donor site of the intron following exon 10. These 
pathogenic mutations either reduce the ability of tau to bind to microtubules or alter the 
splicing of exon 10 resulting in increased 4 repeat tau isoforms (Hutton et al., 1998). To 
date more than 20 different tau gene mutations have been identified in a large number of 
FTDP-17 families. The identification of these mutations provided direct evidence that tau 
dysfunction per se is sufficient to cause neurodegeneration (Hutton et al., 1998; Poorkaj et 
al., 1998; Spillantini et al., 1998; Clark et al., 1998), presumably due to failure of the self-
assembled tau to regulate the microtubule dynamics essential for cell survival (Lee et al., 
2001). Notably, the exact form of tau which causes neuronal degeneration is now being re-
examined (Duff and Planel, 2005), with data emerging that the soluble aggregated species, 
akin to soluble Aβ oligomers, might represent the best target. 
 
 
1.2.4. Origin of Aβ proteins: cell biology of APP 
 
APP is a type-I integral transmembrane glycoprotein that is ubiquistouly expressed, and is 
encoded by a gene located on chromosome 21 (Masters et al., 1985). Alternative splicing of 
the APP gene gives rise to at least three transcripts that encode proteins of 695, 751 and 770 
amino acids (Hardy, 1997; Selkoe, 1999). The two longer isoforms contain a motif which is 
homologous to the Kunitz-type of serine protease inhibitors (KPI) (Kitaguchi et al., 1988; 
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 Ponte el al., 1988; Tanzi et al., 1988), whereas the shorter form of 695 amino acids lacks 
this 56-residue Kunitz domain (Golde et al., 1990). All of the APP isoforms contain the 39-
43 amino acids long Aβ domain. The shorter form of 695 amino acids is the main isoform 
expressed in neurons (Golde et al., 1990). At present the physiological function of APP in 
the brain remains unclear, although it has been proposed to have functions in 
transmembrane signal transduction (Nishimoto et al., 1993), cell proliferation and adhesion 
(Saitoh et al., 1989), calcium regulation (Mattson et al., 1993) and neurite outgrowth 
(Milward et al., 1992). 
 
Figure 4. Pathways processing the APP by α-, β- and γ-secretases. Cleavage by α-secretase does not result
in Aβ production but in release of soluble APPsα and retention of a 83-residue C-terminal peptide (C83).
Cleavage by β-secretase produces soluble APPsβ and a 99-residue C-terminal (C99). Both C83 and C99 are
substrates for γ-secretase that yields a 3-kD peptide called p3 from cleavage of C83, and Aβ from cleavage
of C99. 
 
 
A characteristic feature of APP is its proteolytic cleavage by the α-, β- and γ-secretases 
(Figure 4) (Selkoe, 2001). The differential actions of these secretases lead either to the non-
amyloidogenic or amyloidogenic pathway. α-secretase cleaves APP within the Aβ region to 
produce the soluble α-APPs and the 83-residue COOH-terminal fragment C83 (Esch et al., 
1990; Sisodia et al., 1990). The α-cleavage pathway is considered as default, non-
amyloidogenic pathway. The β-secretase (or BACE for β-site APP-cleaving enzyme) 
 22
 cleavage corresponds to the alternative, amyloidogenic pathway, that produces a 99-residue 
COOH-terminal fragment C99 and the soluble β-APPs (Sinha et al., 1999; Vassar, 1999). 
Both the C83 and C99 fragments remain anchored in the membrane where they are 
processed by γ-secretase to produce p3 from C83 or Aβ from C99. γ-secretase cleavage is 
not sequence specific resulting in Aβ peptides of varying length (Selkoe, 2001). 
 
 
1.2.5. Human tau gene and protein isoforms 
 
Tau proteins belong to the microtubule-associated proteins family (MAP) and are abundant 
in both central and peripheral nervous system neurons, although reports have suggested that 
tau can be expressed in other cell types (Weingarten et al., 1975; Schoenfeld and Obar, 
1994; Tucker, 1990; LoPresti et al., 1995; Wakabayashi et al., 2006). As part of the 
cytoskeleton, tau proteins bind to microtubules and function to stabilize microtubules in the 
polymerized state as well to facilitate the polymerization of tubulin subunits (Drechsel et 
al., 1992; Cassimeris, 1993; Ludin and Matus, 1993; Goode and Feinstein, 1994). The 
human tau gene is located on the chromosome 17 (Neve et al., 1986) and contains 16 exons 
(Figure 5, A) with the major tau protein isoforms being encoded by 11 of them (Andreadis 
et al., 1992; Buee et al., 2000). Through alternative messenger RNA splicing of exons 2, 3 
and 10 (Figure 5, B) a set of six isoforms ranging from 352 to 441 amino-acids are 
generated in adult human brain (Figure 5, C) (Himmler et al., 1989; Kosik, 1989). Exons 9-
13 encode four microtubule-binding motifs which are imperfect repeats of 31 or 32 amino 
acids in the carboxy terminal half of the tau molecule. The alternative splicing of exon 10 
thus generates tau protein isoforms with either three (3R) or four (4R) microtubule-binding 
repeats. Further, the 6 isoforms differ by alternative splicing of exons 2 and 3 resulting in 
the absence (0N) or presence of one (1N) or two (2N) 29 amino acid inserts in the amino-
terminal half of the tau molecule. Thus, alternative splicing of exons 2, 3 and 10 allows for 
six combinations: the longest 441-amino acids (4R2N), 410-amino acids (3R2N), 412-
amino acids (4R1N), 381-amino acids (3R1N), 393-amino-acids component (4R0N) and 
the shortest 352-amino acids isoform (3R0N). Each of these isoforms is likely to have 
particular physiological roles since they are differentially expressed during development 
(Kosik et al., 1989). Also, the degree of phosphorylation is developmentally regulated. 
Thus, tau from fetal brain is phosphorylated at more sites than tau from adult brain (Buée et 
al., 2000). 
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Figure 5. Schematic representation of the human tau gene (A), the tau primary transcript (B) and the six tau
isoforms (C). The human tau gene is located on the long arm of the chromosome 17 at position 17q21 and
contains 16 exons, with exon –1 is a part of the promoter. (B) The Tau primary transcript contains 13 exons,
since exons 4A, 6 and 8 are not transcribed in human. (C) Through alternative messenger RNA splicing of
exons 2, 3 and 10 a set of six isoforms ranging from 352 to 441 amino-acids are generated in adult human
brain The six tau isoforms differ by the absence or presence of one or two 29 amino acids inserts encoded by
exon 2 (green box) and 3 (dark red boxes) in the amino-terminal part, in combination with either three or four
repeat-regions (black boxes) in the carboxy-terminal part. The fourth microtubule-binding domain is encoded
by exon 10 (orange box). 
Tau proteins contain two functional domains (Buée et al., 2000). The amino-terminal part 
of tau proteins, referred to as projection domain, interacts with cytoskelatal elements to 
determine spacings between microtubules in axons (Brandt et al., 1995; Hirokawa et al., 
1988). The amino-terminal part is also involed in signal transduction pathways by 
interacting with proteins as phospholipase C-γ (Hwang et al., 1996). The carboxy-terminal 
part, referred to as microtubules binding domain, regulates the rate of microtubules 
polymerization (Butner and Kirschner, 1991; Goedert and Jakes, 1990). It is also involved 
in the binding with functional proteins as protein phosphatase 2A (Sontag et al., 1999) or 
presenilin-1 (Takashima et al., 1998). 
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 1.2.6. Transgenic mouse models of Alzheimer’s disease 
 
The identification and sequencing of APP and PS genes has provided new opportunities to 
explore pathogenic mechanisms and treatments of AD using genetically engineered mice. 
Multiple lines of transgenic mice expressing mutated human APP now exist that develop 
age-dependent cerebral Aβ-amyloidosis concomitantly with additional AD-like pathologies 
such as memory deficits, gliosis, regional neuronal loss, cerebral amyloid angiopathy and 
dystrophic neurites (Games et al., 1995; Hsiao et al., 1996; Sturchler-Pierrat et al., 1997; 
Calhoun et al., 1998; Stalder et al., 1999; Moechars et al., 1999; Bronfman et al., 2000; 
Kumar-Singh et al., 2000; Van Dorpe et al., 2000; Bondolfi et al., 2002; Kelly et al., 2003). 
In addition to mice expressing mutations in the APP gene, mouse models bearing PS 
mutations have been generated (Duff et al., 1996; Citron et al., 1997). Except for increased 
production of Aβ42/43, no pathological phenotype could be observed. Other models 
combine the insertion of mutated APP with an insertion of mutated PS1 that lead to 
accelerated amyloid plaque deposition (Figure 7) (Borchelt et al., 1996, 1997; Holcomb et 
al., 1998; Lamb et al., 1999; Chishti et al., 2001; Gordon et al., 2002). Several of these Aß 
depositing mouse models develop hyperphosphorylated tau-positive structures around 
plaques but all of them consistently fail to show intracellular filamentous deposits of tau 
protein, which are an essential hallmark of AD. The difference in tau sequence between 
mouse and humans may explain why despite the progressive and severe Aβ deposition 
there are no neurofibrillary tangles and very little neuronal loss in these APP models 
(Hsiao, 1996; Irizarry et al., 1997). 
 
As APP transgenic models failed to develop insoluble tau aggregates, tau transgenic mice 
have been developed. The first transgenic tau models expressing wild-type human tau were 
generated before pathogenic tau mutations had been identified (Gotz et al., 1995; Brion et 
al., 1999; Spittaels et al., 1999; Probst et al., 2000). Overexpressing the 3 or 4 repeat wild-
type human tau in these models resulted in hyperphosphorylation of tau and 
somatodendritic localization; however, none of these transgenic mice developed 
neurofibrillary tangles. The discovery of mutations in the tau gene in FTDP-17 has 
provided the basis for the generation of transgenic mouse models that exhibit age-related 
filamentous tau deposits through expression of mutant human tau protein (Lewis et al., 
2000; Gotz et al., 2001; Hutton et al., 2001). Among others models, Lewis and al. (2000) 
developed transgenic mice expressing the shortest 4 repeat (4R0N) tau with the P301L 
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 mutation under control of the mouse prion promoter. These mice developed motor and 
behavioural deficits accompanied by age- and gene dose-dependent accumulation of 
neurofibrillary tangles (Figure 8) in both brain and spinal cord, with associated 
neurodegeneration and reactive gliosis (Lewis et al., 2000). Using a transgenic line 
expressing the longest 4 repeat (4R2N) tau with the same mutation under the mouse Thy1.2 
promoter, Götz et al. (2001) reported quite similar results. A recent study also showed a 
correlation between the number of NFT and decline in performance on the Morris water 
maze in transgenic mice expressing the P301L mutation, indicating a detrimental effect of 
NFT on memory (Arendash et al., 2004). The FTDP-17-associated mutation P301S has also 
been used to make mouse models. P301S mutant tau expressed under the mouse Thy1.2 
promoter caused tau hyperphosphorylation and formation of tau filaments in affected brain 
regions. FTDP-17 mutations V337M (Tanemura et al., 2001, 2002) and G272V (Gotz et al., 
2001) also were expressed in transgenic mice. Neurofibrillary lesions and associated 
neurodegeneration were found in neurons of V337M mutant mice (Tanemura et al., 2002), 
while G272V mutant mice developed prominent oligodendroglial tau filament formation 
(Götz et al., 2001). None of these tau depositing mouse models developed deposits of 
amyloid-β protein, suggesting that the neurofibrillary tangles in AD are secondary to Aβ 
production (Hardy et al., 1998) and probably triggered by Aβ (Rapoport et al., 2002). 
 
In an attempt to obtain mouse models that display the entire neuropathological spectrum of 
AD, APP transgenic mice were breed with mice expressing the P301L mutant tau. 
Interestingly double mutant mice exhibited substantially enhanced neurofibrillary tangle 
pathology in limbic areas as compared to single tau mutant mice. Notably, plaque 
formation was unaffected by the presence of the tau lesions (Lewis et al., 2001). Thus, 
amyloid plaques can cause tau tangles, but vice versa tangles do not obligate amyloid 
plaque formation. Recently, triple-transgenic mice harboring mutated PS1 (M146V), APP 
(Swedish) and tau (P301L) transgenes have been created that develop extracellular 
Aβ deposits prior to tangle formation in AD relevant brain regions (Oddo et al., 2003). 
Moreover, treatment of the amyloid pathology in these triple transgenic mice led to a partial 
resolution of tau abnormalities (Oddo et al., 2004). 
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 1.2.7. Treating and preventing Alzheimer’s disease 
 
At present there is no cure for AD. Present-day therapies focus on treating associated 
symptoms, such as depression, agitation, sleep disorders, hallucinations, and delusions 
(Clippingdale et al., 2002). To date, only four medications have been approved for the 
symptomatic treatment of patients with Alzheimer disease. These are tacrine (Cognex, 
Warner-Lambert, Morris Plains, New Jersey); donepezil (Aricept, Eisai, Inc., Teaneck, 
New Jersey, and Pfizer, Inc., New York, New York); rivastigmine (Exelon, Novartis, Basel, 
Switzerland); and galantamine (Reminyl, Janssen, Titusville, New Jersey). All are 
cholinesterase inhibitors that are aimed at counterbalancing deficits in the neurotransmitter 
acetylcholine observed in AD (Emilien et al., 2000). Unfortunately, these drugs induce, at 
best, a very modest effect on cognitive functions and activities of daily living and do do not 
stop the progression of AD (Grutzendler and Morris, 2001). If the amyloid cascade 
hypothesis of AD pathogenesis (Hardy and Allsop, 1991) is correct, the most rational 
strategy to treat the disease would rather involve retarding, halting or even reversing the 
process that leads to increased production of Aβ.  
 
With the identification of the α-, β- and γ- secretases, new approaches to treat AD have 
become possible. Therefore, a promising strategy might be reducing formation of Aβ by 
inhibiting either β- or γ-secretases and/or enhancing α-secretase activity (Xia, 2003). There 
are already potent γ-secretase inhibitors tested in a variety of experimental models (Lanz et 
al., 2004; Wong et al., 2004). Several classes of inhibitors are showing favourable acute 
pharmacokinetics with rapid lowering of plasma and CSF Aβ levels (Anderson et al., 2005; 
Barten et al., 2005) but are also revealing unanticipated effects on synaptic function (Dash 
et al., 2005). New classes of γ-secretase inhibitors continue to be disclosed, as part of the 
attempt to develop compounds that are devoid of side-effects (Gundersen et al., 2005; 
Lewis et al., 2005). The major concern is the inhibition of signaling in the Notch pathway, 
which is important for a variety of cell fate decisions during embryogenesis and also in 
adult tissues (Milner and Bigas, 1999; Doerfler et al., 2001; Sisodia and St George-Hyslop, 
2002; van Es et al., 2005). Compounds that inhibit Aβ formation without affecting Notch 
cleavage may offer new leads for the design of APP-specific γ-secretase inhibitors. The 
development of β-secretase inhibitors has been focused on the discovery and design of 
compounds which target the active site of BACE-1 which is thought to be an ideal 
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 therapeutic target as it catalyses the first step of Aβ production. Furthermore, β-secretase 
knockout mice are apparently normal showing no obvious anatomical or physiological 
abnormalities (Luo et al., 2001; Roberds et al., 2001) except for a dramatic reduction in Aβ 
levels. However, one major challenge for the generation of specific inhibitors is the large 
active site of this secretase (Hong et al., 2000). 
 
A chronic inflammatory response, exemplified by activated microglia, reactive astrocytes, 
complement factors, and increased inflammatory cytokine expression, is associated with 
Aβ deposits in AD brain (Akiyama et al., 2000; Emmerling et al., 2000). Therefore, trials of 
anti-inflammatories in AD have been conducted, and considerable research efforts 
undertaken to examine the effects of anti-inflammatories in a variety of experimental 
models. These include the non-steroidal anti-inflammatory drugs (NSAIDs) (Farias et al., 
2005; Morihara et al., 2005), cannabionoids (Ramirez et al., 2005) and glucocorticoids 
(Boedker et al., 2005). NSAIDs have been suggested to delay the onset and slow the 
progression of AD by inhibiting the cyclooxygenase, and therefore prostaglandin synthesis, 
resulting in reduced inflammatory response (Launer, 2003). Besides an anti-inflammatory 
action, some NSAIDs have also been shown to have direct effects on the cleavage of APP 
by γ-secretase, an effect that is independent of the drugs’ inhibition of cyclooxygenase and 
other inflammatory mediators (Weggen et al., 2001). Some such drugs reduce 
cytopathology in APP tg mice (Lim et al, 2001; Jantzen et al., 2002), perhaps by lowering 
the production of the highly amyloidogenic Aβ (Weggen et al., 2001). However, although 
epidemiological studies suggest that NSAIDs reduce the risk of developing AD, clinical 
trials in patients with mild to moderate AD have been negative (Aisen et al., 2003; Launer, 
2003). 
 
Epidemiological studies suggest that cholesterol-lowering drugs could provide some degree 
of protection from AD and therefore could be an attractive treatment strategy (Jick et al., 
2000; Fassbender et al., 2001). Conversely, high blood cholesterol levels have been 
correlated with a higher risk of developing AD (Kivipelto et al., 2001) and high cholesterol 
diets increase Aβ deposition in transgenic mice and in rabbits (Sparks et al., 1994; Refolo et 
al., 2000). A molecular explanation might be that high cholesterol favors processing of APP 
through the amyloidogenic β-secretase pathway in vitro and in vivo (Simons et al., 1998; 
Fassbender et al., 2001). Inhibitors of cholesterol synthesis (statins) have been shown to 
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 decrease Aβ production resulting in reduced pathology in APP tg mice (Fassbender et al., 
2001; Refolo et al., 2001). However, while some early phase clinical trials with statins have 
shown encouraging results (Masse et al., 2005), others have not (Höglund et al., 2005). 
 
Passive immunization with antibodies against Aβ (Bard et al., 2000; DeMattos et al., 2001; 
Wilcok et al., 2003), or active immunization with Aβ (Schenk et al., 1999; Janus et al., 
2000) were proven to prevent amyloid deposition in young mice but also cleared plaques 
and reduced associated glial and neuronal cytopathology in older animals. Moreover, 
immunization with Aβ was found to protect again or reverse cognitive deficits in mice 
(Janus et al., 2000; Morgan et al., 2000; Younkin, 2001; Dodart et al., 2002). Based on 
these results, Elan Corporation moved into clinical trials with the active Aβ-vaccination 
approach. Toxicological testing in several animal species, and Phase I clinical trials in 104 
AD cases suggested that the vaccination with aggregated Aβ42 was safe (Senior, 2002). 
Therefore, in June 2001, a Phase II trial was begun with 360 early to moderate stage 
Alzheimer’s patients in the United States and Europe. However, the phase IIa clinical trial 
for an AD vaccine (AN-1792) was suspended in January 2002 when 6% of the patients 
developed clinical signs of meningoencephalitis, a potentially deadly inflammation of the 
brain (Munch and Robinson, 2002; Senior, 2002; Nicoll et al., 2003; Orgogozo et al., 
2003). The mechanism of this inflammation is unknown, but the appearance of the 
inflammatory reaction before anti-Aβ antibody production in some patients indicates the 
involvement of a T-cell-mediated immune response to Aβ (Weiner and Selkoe, 2002). 
Despite the serious side effects encountered, autopsy evaluation and cognitive assessment 
of patients involved in the study suggest that immunization might work (Nicoll et al., 
2003). The aborted clinical trial with the AN1972 vaccination approach has provided a 
wealth of clinical information (Gilman et al., 2005; Lee et al., 2005) which will assist 
further development of strategies designed to avoid the auto-immune adverse events (Lee et 
al., 2005b; Racke et al., 2005). Chief among these will be avoidance of T-cell-mediated 
responses (Agadjanyan et al., 2005) and the development of passive immunization 
protocols (Hartman et al., 2005). Passive immunization clinical trials are currently 
underway. In the meantime, novel methods of antigen presentation are being tested 
(Frenkel et al., 2005). Three main possible mechanisms have been suggested to be 
responsible for Aβ clearance: (i) Aβ antibodies enter the CNS and target aggregated 
Aβ deposits where they form immune complexes. The Fc-region of the anti-Aβ antibodies 
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 binds to the Fc-receptors on microglia and induces phagocytosis of the Aβ peptide. (Bard et 
al., 2000); (ii) Aβ antibodies generate a peripheral sink for efflux of Aβ out of CNS 
compartments, reducing the potential for aggregation and deposition (DeMattos et al., 
2001); (iii) Aβ antibodies prevent the fibrillar aggregation of Aβ and/or neutralize 
Aβ fibers (Solomon et al., 1996; 1997). 
 
Excessive phosphorylation of the tau protein in AD is thought to cause formation of 
insoluble tau filaments with resulting neurofibrillary tangles, disruption of microtubules, 
and subsequent neuronal dysfunction (Trojanowski and Lee, 2002). Thus, drugs targeted to 
preventing neurofibrillary pathology may help slow progression of cell death. Identification 
of such agents is still in very early stages, but some efforts are focused on agents that might 
decrease abnormal phosphorylation of tau and/or prevent the loss of microtubule structure. 
Inhibition of proline-directed kinases has become a major focus for drug development. Of 
the proline-directed kinases, glycogen synthase kinase β (GSK3β) and cyclin-dependent 
kinase 5 (cdk5) are the primary targets for drug discovery efforts because of their 
association with microtubules, their phosphorylation of tau at AD-relevant epitopes, and 
their involvement in apoptotic cascades in various models (Lau et al., 2002a, b). Their 
inhibition would be expected to decrease tau pathology in AD. The finding that valproate, a 
well-established epilepsy and mood-stabilizing medication, inhibits GSK3β (Chen et al., 
1999) has led to proposal that this drug might improve symptoms of or slow progression of 
AD (Loy and Tariot, 2002). Interestingly, lithium, another well-established mood stabilizer, 
has also been shown to inhibit GSK3β (Alvarez et al., 2002). Another recent 
neuroprotective approach emerging from microtubule studies is the development of small 
molecules that stabilize microtubules such as paclitaxel (Taxol). Down regulation of 
expression of the tau gene (Santacruz et al., 2005) or changing the alternative splicing 
(Rodriguez-Martin et al., 2005) could also confer some new strategies. 
 
Although many therapeutic agents are in various stages of development for the treatment of 
AD, the design of clinical trials has been hampered by the difficulty of identifying patients 
early enough on the disease continuum to test new drugs for effectiveness in slowing the 
progression of deterioration. Thus, success in pharmacological interventions hinges on 
developments in both the diagnostic arena and elucidation of the molecular pathogenesis of 
nerve cell death. Moreover, it is extremely unlikely that a single class of compound or 
 30
 targeting a single mechanism of action will be sufficient to treat AD. For this complex 
disease, it is far more likely that a combination of drugs targeting various aspects of the Aβ 
and/or tau pathways will evolve into some form of rational therapy. 
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The objective of this thesis has been to gain new insights into the mechanisms underlying 
the initiation of cerebral Aβ-amyloidosis and neurofibrillary pathology using transgenic 
mouse models of AD. 
 
A major finding of our studies is that cerebral Aβ-amyloidosis can be induced by 
exogenous, Aβ-rich brain extract, and that intrinsic properties of the Aβ in the extract as 
well as of the host are crucial for the induction of Aβ accumulation in brain. The present 
results indicate that Aβ plays a crucial role in β-amyloid induction in vivo, but the inability 
of synthetic Aβ to potently stimulate protein deposition suggests that β-amyloid induction 
is dependent on a conformation of Aβ and/or cofactors that are specific to the brain. The 
identification of potential conditions and chaperones that are necessary to transform 
synthetic Aβ into a potent amyloid-inducing agent will be crucial for the understanding of 
the in vivo mechanisms of cerebral Aβ-amyloidosis. Moreover, our findings demonstrate 
that the nature of the host is important for the exogenous induction of cerebral Aβ-
amyloidosis and support the possibility that Aβ can form multiple proteopathic strains 
reminiscent of prions. Together, this work also adds indirect support to therapeutic efforts 
targeted at early-stage amyloid formation. 
 
A second important observation is that neurofibrillary pathology, akin to Aβ-amyloidosis, 
can also be induced in vivo by intracerebral infusion of Aβ-rich brain extract into a 
susceptible transgenic host. The finding that human extract with low Aβ levels had no tau-
inducing activity indicates that soluble Aβ species are potent effectors of tau pathology in 
vivo and further supports the hypothesis that a similar interaction occurs in AD. It remains 
to be determined whether a particular Aβ assembly is responsible for the induction of tau 
phenotype. Moreover, our results do not exclude the possibility that factors other than Aβ 
could also induce neurofibrillary pathology in brain, in view of the many tauopathies 
associated with neurofibrillary lesions in the absence of Aβ pathology. In this regard, the 
intracerebral infusion of brain extracts from patients affected by frontotemporal dementia or 
other demented conditions could help to identify such tau-inducing candidates. 
 
In a third set of experiments, we have provided a thorough characterization of the kinetics 
of the microglial response to amyloid pathogenesis in the living brain via multiphoton 
microscopy.  The observation that plaque-associated microglia remain very motile at the 
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plaque-glial interface and exhibit signs of uptake of the Aß peptide, provides compelling 
evidence of a dynamic process of homeostasis. Notably, the interaction of microglia with 
plaques could be stimulated by intracerebral infusion of Aß antibody, such that these cells 
adopted a more macrophagic morphology and were induced to clear existing amyloid 
deposits. Together, our results highlight the dynamic nature of microglia surrounding 
amyloid plaques and indicate that these cells are capable of Aβ clearance in vivo, holding 
great potential for the fight against AD. 
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ABBREVIATIONS 
 
 
 
Aβ  beta-amyloid 
AD  Alzheimer’s disease 
ApoE  apolipoprotein E 
APP  amyloid precursor protein 
BACE  β-site of APP cleaving enzyme 
CA  Cornu Ammonis 
Cdk5  cyclin-dependent kinase 5 
CD  cluster of differentiation molecule 
CNS  central nervous system 
DNA  deoxyribonucleic acid 
FAD  familial Alzheimer’s disease 
FTDP-17 frontotemporal dementia and parkinsonism linked to chromosome 17 
GSK3β glycogen synthase kinase β 
HLA-DR human lymphocyte antigen-classII-DR 
KPI  Kunitz-type of serine protease inhibitor 
MAP  microtubule-associated protein 
NFL(s) neurofibrillary lesion(s) 
NFT(s) neurofibrillary tangle(s) 
NSAIDs non-steroidal anti-inflammatory drugs 
NT(s)  neuropil thread(s) 
PHF(s)  paired helical filament(s) 
PS1  presenilin-1 
PS2  presenilin-2 
RNA  ribonucleic acid 
SF(s)  straight filament(s) 
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